Organovo Holdings, Inc. (ONVO)

NASDAQ: ONVO · IEX Real-Time Price · USD
1.52
-0.04 (-2.56%)
At close: Dec 2, 2022 4:00 PM
1.53
+0.01 (0.66%)
After-hours: Dec 2, 2022 4:07 PM EST

Company Description

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease.

Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds.

The company was incorporated in 2007 and is headquartered in Solana Beach, California.

Organovo Holdings, Inc.
Organovo Holdings logo
Country United States
Founded 2007
Industry Biotechnology
Sector Health Care
Employees 20
CEO Mr. Taylor Crouch

Contact Details

Address:
11555 Sorrento Valley Road, Suite 100
San Diego, California 92121
United States
Phone 858-224-1000
Website organovo.com

Stock Details

Ticker Symbol ONVO
Exchange NASDAQ
Fiscal Year End March
Reporting Currency USD
CIK Code 0001497253
CUSIP Number 68620A203
ISIN Number US68620A2033
Employer ID 27-1488943
SIC Code 2836

Key Executives

Name Position
Keith E. Murphy Executive Chairman
Dr. Jeffrey N. Miner Chief Scientific Officer
Thomas Einar Jurgensen J.D., MS General Counsel and Corporate Secretary
Vaidehi Joshi Director of Discovery Biology and Director
Thomas P. Hess CPA, MBA President and Chief Financial Officer
Dr. Curtis M. Tyree Ph.D. Senior Vice President of Strategy and Business Development

Latest SEC Filings

Date Type Title
Nov 10, 2022 10-Q Quarterly Report
Oct 25, 2022 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Oct 25, 2022 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Oct 25, 2022 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Oct 25, 2022 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Oct 25, 2022 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Oct 25, 2022 S-8 Securities to be offered to employees in employee benefit plans
Oct 14, 2022 8-K Current Report
Sep 22, 2022 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 22, 2022 DEFR14A Filing